The expression of glycogen synthase kinase -3 (GSK-3), a critical molecule modulating major hallmarks of AD, is reported to be decreased on apigenin (50 mg/kg) administration resulting in suppressed BACE1 expression and reduced tau hyperphosphorylation [100]. The gene discussed is MAPT; the disease is Alzheimer disease.